Tuesday, June 7, 2016

FDA Advisors OK Abuse-Deterrent Opioid, Despite Concerns

(MedPage Today) -- Panel backs Vantrela but wants better outcome measures for product class
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)